Skip to content

LivaNova LIVN Derivative Liability, Current

Derivative Liability, Current at other companies

ICU Medical logo
ICU MedicalICUI
Edwards Lifesciences logo
Edwards LifesciencesEW

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesCurrent.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's derivative liability, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's derivative liability, current?
LivaNova (LIVN) reported derivative liability, current of $613K in Q1 2026.
How has LivaNova's derivative liability, current changed year-over-year?
LivaNova's derivative liability, current decreased by 31.4% year-over-year, from $893K to $613K.
What is the long-term trend for LivaNova's derivative liability, current?
Over 5 years (2020 to 2025), LivaNova's derivative liability, current has grown at a -57.8% compound annual growth rate (CAGR), from $7.37M to $99K.